WO1996026181A1 - Derives d'aminotetralone et leurs procede de production - Google Patents
Derives d'aminotetralone et leurs procede de production Download PDFInfo
- Publication number
- WO1996026181A1 WO1996026181A1 PCT/JP1996/000390 JP9600390W WO9626181A1 WO 1996026181 A1 WO1996026181 A1 WO 1996026181A1 JP 9600390 W JP9600390 W JP 9600390W WO 9626181 A1 WO9626181 A1 WO 9626181A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- added
- acid
- reaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/41—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
Definitions
- the present invention relates to an aminotetralone derivative which is an intermediate for producing an antitumor agent camptothecin derivative (see JP-A-6-87746) and a method for producing the same.
- camptothecin derivatives include, for example, 8-amino-6-fluoro-5-methyl-2-protected amino 1-tetralone and (4S) -4-ethyl-7,8-dihydroxy 4-hydroxy 1H-pyrano [3 , 4— f] indidine-1, 3, 6, 1 0
- the present invention provides a method for obtaining an 8 -amino 2 -protected amino-1 -tetralone derivative which is a useful synthetic intermediate for industrial production of camptothecin derivatives in a simple and high yield. Aim. Disclosure of the invention
- the present inventors have conducted intensive studies and found that the use of a palladium-based catalyst allows efficient reduction of the carbonyl group, and that the acid treatment allows the 8-position-protected amino compound of the 2,8-diprotected amino compound to be reduced. That the protecting group of the group can be selectively separated, and that the 8-amino-2-protected amino-1-tetraopene derivative can be obtained in a short step and in high yield without passing through an unstable 2,8-diamino compound.
- the present invention has been completed.
- the method for producing the 8-amino-2-protected amino-1-tetralone derivative (5) according to the present invention can be represented by the following reaction formula.
- R 1 and R 2 each independently represent a hydrogen atom, a halogen atom, a hydroxyl group or an alkyl group having 1 to 6 carbon atoms, X and Y each independently represent an amino group having a protecting group, n is an integer from 0 to 4)
- the compound (1) is hydrogenated in the presence of a palladium catalyst to obtain a compound (2), and the compound (2) is oxidized to a compound (3), and then protected and aminated to obtain a compound (4). Then, the compound (5) is produced by reacting the compound (4) with an acid to remove only the protecting group of the 8-amino group.
- a palladium catalyst to obtain a compound (2)
- the compound (2) is oxidized to a compound (3), and then protected and aminated to obtain a compound (4).
- the compound (5) is produced by reacting the compound (4) with an acid to remove only the protecting group of the 8-amino group.
- the step of obtaining the compound (4) from (2) is described in, for example, JP-A-6-87764. Accordingly, the present invention provides a method for producing compound (2) from compound (1) and a method for producing compound (5) from compound (4).
- R 1 and R 2 include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a fluorine atom, a chlorine atom, and a bromine atom. It is particularly preferable that R 1 is a methyl group and R 2 is a fluorine atom. Also, n is particularly preferably 2.
- Examples of the protecting group of the protected amino group represented by X and Y include an alkoxycarbonyl group such as a tertiary butoxycarbonyl group, a 2,2,2-trichloromouth ethoxyquincarbonyl group; a benzyloquinecarbonyl group and a paramethoxy group.
- Aralkyloxycarbonyl groups such as benzyloxycarbonyl group and p-nitrobenzyloquincarbonyl group; acetyl group, methoxyacetyl group, trifluoroacetyl group, chloroacetyl group, bivaloyl group, formyl group, benzoyl group, etc.
- alkyl group such as a tertiary butyl group, a benzyl group, a nitro group, a lanitrobenzyl group, a paramethoxyquinbenzyl group, a triphenylmethyl group, or an aralkyl group; a methanesulfonyl group, a trifluoromethanesulfonyl group Alkylsulfonyl groups or halogenoalkylsulfonyl groups such as benzene; Ruhoniru group, toluenesulfonyl force Ashiru group can ⁇ Ge Rukoto a ⁇ Li one Rusuruhoniru group such as a group, particularly good Arukanoiru group optionally halogen substituted, Benzoiru group are preferable.
- the starting compound (1) can be produced, for example, according to the following reaction formula.
- R 3 represents a hydrogen atom or a carboquine protecting group, and R 1 , R 2 , n and X are the same as described above.
- the compound (7) is reacted with a dicarboxylic anhydride such as succinic anhydride in the presence of a Lewis acid to obtain a compound (8), and the compound (8) is hydrogenated in the presence of a palladium catalyst to obtain a compound (9)
- the compound (9) is reduced in the presence of an acid to obtain a compound (10), and the compound (10) is reacted with hydroquinamine to give the compound (10).
- (10) can also be obtained by reacting compound (7) with 7-butyrolactone in the presence of an acid catalyst.
- Compound (2) is obtained by hydrogenating compound (1) in the presence of a palladium catalyst. This reaction can be carried out under acidic or neutral conditions, or under different conditions.
- compound (1) is dissolved in a solvent, activated carbon and palladium chloride are mixed with a solution of the same in an acid, and the mixture is stirred under a hydrogen gas atmosphere and hydrogenated. do it.
- the solvent is not particularly limited as long as it is inert to the hydrogenation reaction, and preferably includes a solvent that is miscible with water.
- a solvent that is miscible with water for example, alcohols such as methanol, ethanol, and isopropyl alcohol; ethers such as dioxane and tetrahydrofuran; acetic acid and ethyl acetate;
- the amount of the solvent used is preferably 5 to 100 times the amount of the compound (1) (volume Z weight, 1 time when the solvent is used for 1 gram of the compound (1)). Is 10 to 30 times.
- the acid for preparing the palladium chloride solution may be an inorganic acid, but usually hydrochloric acid or sulfuric acid can be used.
- the concentration of such acid is 5% by weight or more, and preferably 15 to 25% by weight.
- the acid is used in an amount of 3 to 10 times, preferably about 5 times the weight of palladium chloride.
- the amount of palladium chloride used is 0.01 to 0.1 equivalent to compound (1). (Mol), preferably about 0.03 equivalent.
- Activated carbon is commercially available in normal as activated carbon, the amount of it or be c activated carbon using shall 1 0 times the weight 3 with respect to palladium chloride, preferably 5-fold amount of about twice.
- Hydrogen gas may be at atmospheric pressure, but may be reacted under pressure.
- Hydrogenation can be carried out at room temperature to about 50 ° C., preferably at room temperature, with stirring for 1 hour to several days, preferably for about 5 hours.
- the compound (1) may be dissolved in a solvent, and the mixture of the solution and the palladium-carbon catalyst may be stirred and hydrogenated under a pressurized hydrogen gas atmosphere.
- the solvent is not particularly limited as long as it is inert to the hydrogenation reaction.
- examples thereof include alcohols such as methanol, ethanol, and isopropyl alcohol; ethers such as dioxane and tetrahydrofuran; and acetic acid and ethyl acetate. And the like.
- the amount of the solvent to be used and the like are the same as those in the above method using chloride and radium.
- the palladium-carbon catalyst may be a carbon-supported catalyst.
- the palladium content is preferably 5 to 10% in the catalyst, and is preferably about 0.2 equivalent (mole) to the compound (1). It may be carried out in a sealed container such as an autoclave, and a hydrogen gas pressure of 10 to 100 atm, particularly preferably about 40 atm, room temperature to 100 ° C, particularly about 50 ° C, and about 1 hour to It is preferable to carry out for several days.
- the compound (4) can be obtained by oxidizing the compound (2) with potassium permanganate or the like and then aminating the compound, and then performing acetylation or the like by a known method (JP-A-6-87764). The method may be performed according to
- Compound (5) may be obtained by treating compound (4) with an acid.
- the acid include inorganic acids such as dilute hydrochloric acid, dilute sulfuric acid, and hydrobromic acid; and organic acids such as acetic acid, trifluoroacetic acid, and methanesulfonic acid.
- the amount of the acid used is preferably about 10 times the amount of the compound (4) (volume Z weight). These acids can also serve as a solvent.
- An inert solvent can be used for the acid treatment of compound (4).
- examples thereof include alcohols, dioxane, and tetrahydrofuran.
- the acid treatment is carried out at room temperature to 100 ° C., preferably 60 ° C., for 1 to 24 hours, particularly preferably about 2 hours.
- Example 4 A total amount of 7-fluoro-6-methyl-1-tetralone obtained in Example 4, Method 2 was used as an aqueous solution of 10.6 g of hydroxyammonium chloride and 12.6 g of sodium acetate. (Water 5 ⁇ ), and then ethanol 30 was added, and the mixture was stirred at an external temperature of 70 to 75 for 3 hours. After completion of the reaction, the solvent was distilled off under reduced pressure, and water was added, and the precipitated crystals were collected by filtration. After washing with water, drying under reduced pressure gave 15.3 g of the title compound.
- the manganese dioxide c that was removed by filtration was thoroughly washed with chloroform, the filtrate was distilled off under reduced pressure, and the obtained residue was dissolved in chloroform.Then, washed three times with saturated aqueous sodium hydrogen carbonate and washed with potassium carbonate. And dried. The solvent was distilled off under reduced pressure, and the obtained residue was recrystallized from chloroform-formyl ether to obtain 2.6 g of the title compound.
- Aminotetralone derivatives which are synthetic intermediates useful for industrial production of camptothecin derivatives, can be obtained in a simple and high yield.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96903202A EP0811603B1 (en) | 1995-02-22 | 1996-02-21 | Aminotetralone derivatives and process for producing the same |
AT96903202T ATE227703T1 (de) | 1995-02-22 | 1996-02-21 | Aminotetralon-derivate und verfahren zu deren herstellung |
EA199700189A EA000122B1 (ru) | 1995-02-22 | 1996-02-21 | Способ получения замещенных производных бензола |
US08/894,230 US5849945A (en) | 1995-02-22 | 1996-02-21 | Aminotetralone derivatives and preparation process thereof |
DE69624796T DE69624796T2 (de) | 1995-02-22 | 1996-02-21 | Aminotetralon-derivate und verfahren zu deren herstellung |
DK96903202T DK0811603T3 (da) | 1995-02-22 | 1996-02-21 | Aminotetralonderivater og fremgangsmåder til fremstilling af samme |
NO973842A NO973842D0 (no) | 1995-02-22 | 1997-08-21 | Aminotetralonderivater og fremgangsmåter for fremstilling derav |
FI973434A FI973434A (fi) | 1995-02-22 | 1997-08-21 | Aminotetralonijohdannaisia ja menetelmä niiden valmistamiseksi |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3337695 | 1995-02-22 | ||
JP7/33376 | 1995-02-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996026181A1 true WO1996026181A1 (fr) | 1996-08-29 |
Family
ID=12384880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/000390 WO1996026181A1 (fr) | 1995-02-22 | 1996-02-21 | Derives d'aminotetralone et leurs procede de production |
Country Status (14)
Country | Link |
---|---|
US (1) | US5849945A (ja) |
EP (1) | EP0811603B1 (ja) |
KR (1) | KR100406020B1 (ja) |
CN (1) | CN1104409C (ja) |
AT (1) | ATE227703T1 (ja) |
CA (1) | CA2213201A1 (ja) |
DE (1) | DE69624796T2 (ja) |
DK (1) | DK0811603T3 (ja) |
EA (1) | EA000122B1 (ja) |
ES (1) | ES2187634T3 (ja) |
FI (1) | FI973434A (ja) |
NO (1) | NO973842D0 (ja) |
PT (1) | PT811603E (ja) |
WO (1) | WO1996026181A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011109464A1 (en) | 2010-03-02 | 2011-09-09 | Concert Pharmaceuticals Inc. | Deuterated tetrahydronaphthalene derivatives |
WO2013036434A1 (en) | 2011-09-07 | 2013-03-14 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives as t-type calcium channel blocker |
WO2019044946A1 (ja) | 2017-08-31 | 2019-03-07 | 第一三共株式会社 | 抗体-薬物コンジュゲートの新規製造方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7210770B2 (ja) | 2019-03-29 | 2023-01-23 | メドイミューン・リミテッド | 化合物及びその複合体 |
CN114516808B (zh) * | 2020-11-20 | 2024-01-19 | 华东师范大学 | 一种氨基保护的苯并环酮类化合物的制备方法 |
CN115703712A (zh) * | 2021-08-17 | 2023-02-17 | 江苏迈威康新药研发有限公司 | 5,8-二氨基-3,4-二氢-2h-1-萘酮的合成方法以及其中采用的中间体化合物 |
CN115724758A (zh) * | 2021-08-24 | 2023-03-03 | 杭州中美华东制药有限公司 | 喜树碱衍生物中间体及其合成方法和利用中间体合成喜树碱衍生物的方法 |
WO2023072143A1 (zh) * | 2021-10-26 | 2023-05-04 | 上海弼领生物技术有限公司 | 一种喜树碱类衍生物中间体、其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0559061A (ja) * | 1991-01-16 | 1993-03-09 | Dai Ichi Seiyaku Co Ltd | 六環性化合物 |
JPH0687746A (ja) * | 1992-07-16 | 1994-03-29 | Dai Ichi Seiyaku Co Ltd | 抗腫瘍剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5658920A (en) * | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
-
1996
- 1996-02-21 DE DE69624796T patent/DE69624796T2/de not_active Expired - Fee Related
- 1996-02-21 KR KR1019970705743A patent/KR100406020B1/ko not_active IP Right Cessation
- 1996-02-21 WO PCT/JP1996/000390 patent/WO1996026181A1/ja active IP Right Grant
- 1996-02-21 CA CA002213201A patent/CA2213201A1/en not_active Abandoned
- 1996-02-21 DK DK96903202T patent/DK0811603T3/da active
- 1996-02-21 US US08/894,230 patent/US5849945A/en not_active Expired - Fee Related
- 1996-02-21 ES ES96903202T patent/ES2187634T3/es not_active Expired - Lifetime
- 1996-02-21 PT PT96903202T patent/PT811603E/pt unknown
- 1996-02-21 EP EP96903202A patent/EP0811603B1/en not_active Expired - Lifetime
- 1996-02-21 AT AT96903202T patent/ATE227703T1/de not_active IP Right Cessation
- 1996-02-21 CN CN96192090A patent/CN1104409C/zh not_active Expired - Fee Related
- 1996-02-21 EA EA199700189A patent/EA000122B1/ru not_active IP Right Cessation
-
1997
- 1997-08-21 NO NO973842A patent/NO973842D0/no not_active Application Discontinuation
- 1997-08-21 FI FI973434A patent/FI973434A/fi unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0559061A (ja) * | 1991-01-16 | 1993-03-09 | Dai Ichi Seiyaku Co Ltd | 六環性化合物 |
JPH0687746A (ja) * | 1992-07-16 | 1994-03-29 | Dai Ichi Seiyaku Co Ltd | 抗腫瘍剤 |
Non-Patent Citations (1)
Title |
---|
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNUCATIONS, Vol. 43, No. 12, (1978), O. EXNER et al., "Electrostatic Effects on Ionization Equilibriums. Carboxylic Acids and Amines Derived from 1-Indanone", pages 3227-3240. * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011109464A1 (en) | 2010-03-02 | 2011-09-09 | Concert Pharmaceuticals Inc. | Deuterated tetrahydronaphthalene derivatives |
EP3144296A1 (en) | 2010-03-02 | 2017-03-22 | Concert Pharmaceuticals, Inc. | Deuterated tetrahydronaphthalene derivatives |
WO2013036434A1 (en) | 2011-09-07 | 2013-03-14 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives as t-type calcium channel blocker |
WO2019044946A1 (ja) | 2017-08-31 | 2019-03-07 | 第一三共株式会社 | 抗体-薬物コンジュゲートの新規製造方法 |
KR20200033949A (ko) | 2017-08-31 | 2020-03-30 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 신규 제조 방법 |
US11318212B2 (en) | 2017-08-31 | 2022-05-03 | Daiichi Sankyo Company, Limited | Method for producing antibody-drug conjugate |
KR20220104292A (ko) | 2017-08-31 | 2022-07-26 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 신규 제조 방법 |
TWI806895B (zh) * | 2017-08-31 | 2023-07-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之新穎製造方法 |
KR20240018674A (ko) | 2017-08-31 | 2024-02-13 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 신규 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
DE69624796T2 (de) | 2003-04-03 |
ATE227703T1 (de) | 2002-11-15 |
NO973842L (no) | 1997-08-21 |
KR100406020B1 (ko) | 2004-03-20 |
ES2187634T3 (es) | 2003-06-16 |
EA199700189A1 (ru) | 1998-02-26 |
FI973434A0 (fi) | 1997-08-21 |
DE69624796D1 (de) | 2002-12-19 |
CA2213201A1 (en) | 1996-08-29 |
CN1104409C (zh) | 2003-04-02 |
NO973842D0 (no) | 1997-08-21 |
US5849945A (en) | 1998-12-15 |
CN1175943A (zh) | 1998-03-11 |
KR19980702346A (ko) | 1998-07-15 |
EA000122B1 (ru) | 1998-08-27 |
PT811603E (pt) | 2003-03-31 |
EP0811603A4 (en) | 1998-10-07 |
EP0811603B1 (en) | 2002-11-13 |
DK0811603T3 (da) | 2002-12-16 |
FI973434A (fi) | 1997-08-21 |
EP0811603A1 (en) | 1997-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20040018538A (ko) | Uk-2a의 엑소사이클릭 에스테르 또는 이의 유도체의환원성 분해 및 이로부터 형성된 생성물 | |
JP3374155B2 (ja) | 保護−4−アミノメチル−ピロリジン−3−オンの製造方法 | |
WO1996026181A1 (fr) | Derives d'aminotetralone et leurs procede de production | |
WO2001064701A1 (fr) | Procede de preparation de flavonoides | |
JPS6247190B2 (ja) | ||
WO2002020552A1 (fr) | Procédé de préparation de dérivés de prégnane | |
EP1534705A1 (en) | Process for preparing zolmitriptan compounds | |
JP4512100B2 (ja) | 置換ベンゾピラン化合物の製造方法 | |
Anacardio et al. | Palladium-Catalyzed Selective Carbonylation of Vinyl Triflates in the Presence of 2-Iodophenols: A New Route to 3-Spiro-Fused Benzofuran-2 (3H)-ones | |
JPH0316333B2 (ja) | ||
JPH08225482A (ja) | テトラロン関連化合物及びその製法 | |
JP2003514908A (ja) | テトラヒドロ−[1,8]−ナフチリジンに向けた方法および中間体 | |
CN112552307B (zh) | 一种三环内酯c20位羟基化的制备方法 | |
KR100469030B1 (ko) | 시사프라이드의 합성방법 | |
JPWO2004099136A1 (ja) | ピロリジン誘導体の製造方法 | |
Faigl et al. | Efficient methods for optional metalation of 1-(methylphenyl) pyrroles in α or benzylic positions | |
JP3953225B2 (ja) | キノリン誘導体の製造方法 | |
KR100522392B1 (ko) | 그라니세트론 염산염의 제조 방법 | |
JPS63216890A (ja) | チユアンシンマイシン類縁体の製造方法 | |
JPH01319496A (ja) | ウラシル誘導体 | |
KR20240024937A (ko) | Cyp11a1 억제제 및 그의 중간체의 제조 방법 | |
JP2002363180A (ja) | ユーディストミン合成中間体およびその合成方法 | |
HU224817B1 (en) | New process for producing 17-betha-hydroxy-17-alpha-methyl-2-oxa-5-alpha-androstan-3-on and intermediate thereof | |
JPH0656843A (ja) | 5−アシル−4,5,6,7−テトラヒドロチエノ[3,2−c]ピリジン−2−カルボン酸誘導体及びその製造方法 | |
JP2002201199A (ja) | プレグナン誘導体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96192090.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN FI JP KR NO US AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996903202 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2213201 Country of ref document: CA Ref document number: 2213201 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970705743 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08894230 Country of ref document: US Ref document number: 973434 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 199700189 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1996903202 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970705743 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996903202 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970705743 Country of ref document: KR |